HomeTop MoversHere’s to why Verastem Oncology Inc. (VSTM) stock surges during pre-market trading?

Here’s to why Verastem Oncology Inc. (VSTM) stock surges during pre-market trading?

Verastem Oncology Inc. (NASDAQ: VSTM) stock gained by 2.22% at the last close while the VSTM stock price rises by 32.25% in the pre-market trading session. Verastem Oncology is a pharmaceutical firm in the early stages of development dedicated to the research and marketing of innovative medications to enhance the lives of cancer patients.

>> 7 Top Picks for the Post-Pandemic Economy << 

VSTM stock’ Significant Development

Verastem Oncology has scheduled a brief oral presentation that will discuss new findings from the current investigator-sponsored Phase 1/2 FRAME trial. The FRAME trial is looking at VS-6766, a Verastem RAF/MEK inhibitor, in conjunction with defactinib, a Verastem FAK inhibitor, in people with decreased serous ovarian cancer (LGSOC). The data will be discussed at the European Society of Medical Oncology (ESMO) Congress 2021, which will be held from September 16 to 21, 2021.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Read More

Dr Susana Banerjee, MBBS, MA, PhD, FRCP, lead author of the presentation, Team Leader in Women’s Cancers at The Institute of Cancer Research, London, and Consultant Medical Oncologist and Research Lead for The Royal Marsden NHS Foundation Trust Gynaecology Unit said that, Low-grade serous ovarian cancer is an uncommon, slow-growing malignancy that does not react well to chemotherapy or hormone treatment and impacts young women excessively. The findings presented at ESMO this year show that VS-6766 in combination with defactinib keeps showing promising reaction rates in patients with LGSOC, with a 46 percent partial response rate in the overall patient population and a 64 percent partial response rate in patients with KRAS-mutated LGSOC, and manageable side-effect rates.

Brian Stuglik, Chief Executive Officer of Verastem Oncology stated,

The investigator-sponsored FRAME study, whose preliminary findings helped lead the US Food and Drug Administration (FDA) to assign the VS-6766 and defactinib combination as an Innovative Therapy in LGSOC, persists to be critical in laying the groundwork for safety, effectiveness, and longevity in this novel RAS pathway tumour treatment. In individuals that have already taken MEK inhibitors, their findings suggest that combining VS-6766 with defactinib leads in good response rates and median progression-free life.

Related Videos

Must Read

Related News


Please enter your comment!
Please enter your name here